他汀类药物使用可能与肺移植受者侵袭性曲霉病风险降低相关
本回顾性研究纳入2010至2017年785例肺移植受者并随访移植后一年,采用多变量Cox比例风险模型分析他汀使用与侵袭性曲霉病(IA)的关联。结果显示他汀使用与IA风险降低独立相关(P=.002,SHR 0.30,95%CI .14-.64),且与移植后曲霉定植发生率降低相关。
要点
- 他汀使用与肺移植受者IA风险降低独立相关(SHR 0.30,95%CI .14-.64)。
- 他汀组曲霉定植114例(34%) vs 无他汀组123例(27%),P=.038。
- 研究为回顾性设计,他汀使用定义为IA发生前至少2周。
核心结论
- 移植后第一年内使用他汀至少两周与肺移植受者IA风险降低70%相关。
研究设计与样本
- 回顾性研究纳入2010至2017年肺移植受者,随访移植后一年。
- 共纳入785例肺移植受者,44%为女性,平均年龄53岁,最常见基础疾病为肺纤维化(23.8%)。
- 采用多变量Cox比例风险模型分析他汀使用与IA的关联,校正其他已知IA危险因素。
- IA诊断依据ISHLT标准(证实或可能IA)。
- 他汀使用定义为IA发生前至少使用2周。
主要发现
- 451例(57%)移植后接受他汀,阿托伐他汀最常用(68%)。
- 移植后他汀平均使用时长347天(IQR 305至346)。
- 55例(7%)在移植后第一年发生IA,其中9例(16.3%)在发生IA前曾使用他汀。
- 多变量分析中他汀使用与IA风险降低独立相关(P=.002,SHR 0.30,95%CI .14-.64)。
- 他汀使用与移植后曲霉定植发生率降低相关:无他汀组114例(34%) vs 他汀组123例(27%),P=.038。
关键数值与推荐
- IA诊断依据ISHLT标准(证实或可能IA)。
- 他汀使用定义为IA发生前至少2周。
- 他汀使用与IA风险降低独立相关(P=.002,SHR 0.30,95%CI .14-.64)。
- 他汀组曲霉定植123例(27%) vs 无他汀组114例(34%),P=.038。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins are competitive inhibitors of 3-hydroxy-3methylglutaryl coenzyme A reductase (HMG-CoA reductase) that catalyses HMG-CoA conversion to mevalonate, a process involved in synthesizing cholesterol in humans and ergosterol in fungi. The effect of statin use on the risk of development of invasive aspergillosis (IA) in lung transplant recipients (LTRs) is not well documented. METHODS: This retrospective study included LTRs from 2010 to 2017 who were followed for one-year post-transplant. Proven or probable IA was diagnosed as per ISHLT criteria. We performed a multivariable Cox proportional hazards model of the association between IA and statin use (minimum of 2 weeks duration prior to IA), adjusting for other known IA risk factors. RESULTS: We identified 785 LTRs, 44% female, mean age 53 years old, the most common underlying disease being pulmonary fibrosis (23.8%). In total, 451 LTRs (57%) received statins post-transplant, atorvastatin was the most commonly used statin (68%). The mean duration of statins post-transplant was 347 days (interquartile range [IQR]: 305 to 346). And 55 (7%) LTRs developed IA in the first-year post-transplant. Out of these 55 LTRs, 9 (16.3%) had received statin before developing IA. In multivariable analysis, statin use was independently associated with a lower risk of IA (P = .002, SHR 0.30, 95% confidence interval [CI] 95% .14-.64). Statin use was also associated with a lower incidence of post-transplant Aspergillus colonization, 114 (34%) in the no statin group vs 123 (27%) in the statin group (P = .038). CONCLUSIONS: The use of statin for a minimum of two weeks during the first-year post-transplant was associated with a 70% risk reduction of IA in LTRs.
引用
- Villalobos AP, Foroutan F, Davoudi S, et al. Statin Use May Be Associated With a Lower Risk of Invasive Aspergillosis in Lung Transplant Recipients. Clin Infect Dis. 2023. PMID: 35900334. doi:10.1093/cid/ciac551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。